PBIO - Pressure BioSciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
3.60
0.00 (0.00%)
As of 3:19PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.60
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume50
Avg. Volume2,849
Market Cap4.16M
Beta2.13
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research6 days ago

    PBIO: Revenue Expected to Continue to Grow

    Total revenue for 3Q17 was $646,061, compared to $535,334 in 3Q16, an increase of $110,727 (21%). This increase was primarily attributable to increases in both instrument and consumable sales. Total revenue included product & services revenue and grant revenue.

  • Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
    Capital Cube3 months ago

    Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Pressure BioSciences, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Pressure BioSciences, Inc. – Waters Corporation, Bruker Corporation, General Electric Company, Harvard Bioscience, Inc., Thermo Fisher Scientific Inc. and PerkinElmer, Inc. (WAT-US, BRKR-US, GE-US, HBIO-US, TMO-US and PKI-US) ... Read more (Read more...)

  • Zacks Small Cap Research6 months ago

    PBIO: Significant Revenue Growth Expected for 2017 and Beyond

    Total revenue for the first quarter 2017 was $0.55 million, as compared to total revenue of $0.51 million for the first quarter 2016, an increase of 8.0%. This increase was primarily attributable to an increase of 19% in the sale of instrument systems, from $332,016 in Q1 2016 to $396,095 in the same quarter of 2017. This decrease was primarily due to reduced R&D expenses combined with increased sales of product and services.

  • Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017
    Capital Cube6 months ago

    Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017

    Categories: Yahoo FinanceGet free summary analysis Pressure BioSciences, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Pressure BioSciences, Inc. – Waters Corporation, MOCON, Inc., PerkinElmer, Inc., General Electric Company, Harvard Bioscience, Inc., Thermo Fisher Scientific Inc. and Bruker Corporation (WAT-US, MOCO-US, PKI-US, GE-US, HBIO-US, ... Read more (Read more...)

  • Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017
    Capital Cube8 months ago

    Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017

    Categories: Yahoo Finance Get free summary analysis Pressure BioSciences, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Pressure BioSciences, Inc. – MOCON, Inc., PerkinElmer, Inc., Harvard Bioscience, Inc., Thermo Fisher Scientific Inc. and Bruker Corporation (MOCO-US, PKI-US, HBIO-US, TMO-US and BRKR-US) that have also reported ... Read more (Read more...)

  • Benzingalast year

    Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell

    “In a research lab, one of the most critical parts of scientific research is what we call sample preparation. It is absolutely critical that you are as good as you can be when you’re preparing the sample ...

  • Zacks Small Cap Researchlast year

    PBIO: Update on Third Quarter Financials

    The company expects grant revenue to begin to increase in the fourth quarter of 2016 and continue to increase into 2017. Total revenue decreased to $535,334 in the third quarter 2016 from $580,334 for the third quarter of 2015. Adjusted net loss per common share was $(0.02) for the quarters ended September 30, 2016, compared to net loss per share of (0.03) for third quarter of 2015.